
A medication to treat agitation in Alzheimer’s patients now has approval from the U.S. Food and Drug Administration. The FDA gave supplemental approval to Otsuka Pharmaceutical Company Ltd., and Lundbeck Inc. for Rexulti (brexpiprazole) oral tablets on Thursday. Rexulti is the first FDA-approved treatment for these symptoms. “Agitation is one of the most common and… read on > read on >